Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2000-03-23
2002-03-19
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
06359007
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification of clinical uses of compounds that include L-arginine and various biologically available metalloarginates. In particular, the invention comprises L-arginine, magnesium L-arginate, zinc L-arginate, and copper L-arginate with their ascorbate salts, and their uses as oral nutritional supplements and clinical agents.
2. Description of the Prior Art
(a) L-Arginine and Nitric Oxide (NO)
L-arginine is the precursor amino acid critical to the synthesis of nitric oxide by nitric oxide synthase (cNOS or eNOS), the enzyme responsible for constitutive production of NO by vascular endothelial and neural cells.
Vascular endothelial dysfunction secondary to endothelial stress, ischemia, atherosclerosis, hypertension, aging, diabetes or other etiologies, results in a reduction of the production of NO. Endothelial dysfunction has been well documented in the coronary circulation, and probably also the renal circulation, of patients with essential hypertension and, because of the reduced production of local levels of cNOS, aging alone or aging accompanied by atherosclerosis of the vascular endothelium reduce its ability to produce NO.
NO increases local vascular levels of guanosine 3′,5′-cyclic monophosphate (cGMP), by providing the molecular radical necessary for the production of cGMP via the enzyme guanylate cyclase. Adequate cGMP results in: increased local blood flow, increased smooth muscle relaxation, increases in healthy endothelial cell proliferation, reduced endothelial permeability, inhibition of vascular smooth muscle cell (VSMC) proliferation, inhibition of cellular (both neural and glial) apoptosis and useful alterations in the ciliary muscle and trabecular meshwork of the eye which result in improvements in outflow facility.
There is some evidence that NO alone (also see magnesium, below) modulates intracellular calcium (Ca
+2
) oscillations by blocking endoplasmic reticular Ca
+2
release and by enhancing intracellular Ca
+2
extrusion.
NO is not only helpfully antithrombotic, it also strongly counters the potent endothelial-derived vasoconstrictor, endothelin-1 (ET-1). A fine balance of NO and ET-1 not only mediates local blood flow but also many facets of systemic vascular autoregulation. If NO is reduced, an unopposed tonic, ET-1-induced vasoconstrictive response occurs.
Plasma levels of L-arginine can be increased by oral administration. In young men with coronary artery disease, oral L-arginine has been shown to improve endothelium-dependent dilatation and reduce monocyte/endothelial cell adhesion. Dietary L-arginine improves NO-dependent vasodilator function in cholesterol-fed rabbits and blocks the progression of aortic plaques (see below). This apparently occurs via the restoration of cNOS and a reduction of vascular oxidative stress. Plasma arginine concentration is reduced in diabetic rats but is restored to normal following dietary L-arginine supplementation.
Oral doses of L-arginine raise levels of available NO. In one study, chronic administration of L-arginine (2% in drinking water) appeared to improve endothelium-dependent vasodilator function and systemic NO production and to reduce vascular oxidative stress in cholesterol-fed rabbits with pre-existing hypercholesterolemia.
(b) Magnesium (Mg
+2
)
Mg
+2
deficiencies are widespread in the general population. This is especially true in diabetic patients with normal renal function, in the institutionalized elderly, in chronic alcoholics and smokers, and in populations living in regions with water supplies low in Mg
+2
.
Mg
+2
deficiency has been associated with cardiac arrythmias, hypertension, decreased vascular intraluminal fluidity and vasoconstriction. These pathologies result from a reduction in the efficiency of the modulation of cell membrane Ca
+2
channel gating. By a variety of mechanisms, Mg
+2
modulates the level of both intracellular and extracellular Ca
+2
. Excess cytoplasmic free Ca
+2
has the deleterious effect of leading to an increase in ET-1, with its associated increase in vasoconstriction and cell apoptosis. Mg
+2
optimizes cytoplasmic free Ca
+2
levels without interfering with normal Ca
+2
intracellular signaling. Because vascular endothelial production of ET-1 is highly dependent upon cytosolic Ca
+2
influx via transmembrane Ca
+2
channels, Ca
+2
channel blockade reduces this influx and reduces the production of ET-1.
The eye maintains the equilibrium of intraocular pressure by a dynamic balance between aqueous humor production and aqueous outflow via the trabecular meshwork. If outflow is reduced intraocular pressure rises, and vice versa. Levels of ET-1 are elevated in the aqueous humor of patients with chronic open angle glaucoma, and local production of cNOS is reduced in these eyes. Induced elevations of aqueous ET-1 levels produce optic nerve collapse in rabbits and monkeys. The same critical vasoactive balance between ET-1 and NO appears to be as important in regulating vascular flow within the eye as it is in regulating systemic blood flow. Imbalances that result in uncontested activity of ET-1 because of reduced levels of NO, are strongly implicated in the vascular progression of visual field loss associated with chronic glaucoma.
In addition to these vascular effects, trabecular smooth muscle contraction is produced by ET-1 and strongly opposes the tonic, relaxation properties of NO. As a result, trabecular contraction in the eye is stimulated, resistance to aqueous outflow is increased and IOP increases. At the same time this pressure increase is occurring, putative vasoconstriction of the small vessels of the optic nerve (probably the posterior ciliary arteries) occurs, and the course is set for optic nerve atrophy and blindness.
Clinical confirmation of these findings is found in the fact that exposure of patients to vasodilating stimuli or to Ca
+2
channel blockers has resulted in an improvement of the glaucomatous visual field; a serendipitous reduction of IOP has been observed as a side effect in glaucoma patients using Ca
+2
channel blockers for systemic hypertension. Unfortunately, pharmaceutical Ca
+2
channel blockers used clinically at effective doses have gross, amplitude driven, essentially uncontrolled effects on Ca
+2
cellular signaling. As a result, prescribing pharmaceutical doses of blockers to systemically normotensive glaucoma patients subjects the glaucomatous optic nerve to a significant risk of hypoxia secondary to reduced perfusion pressure and leads to an increased risk of visual loss. The sensitive ability of Mg
+2
to optimize cytoplasmic free Ca
+2
levels permits more delicate control of the modulation of ET-1/NO balances without interfering with normal Ca
+2
intracellular signaling and avoids the risks associated with iatrogenic hypotension.
The correction of an existing Mg
+2
deficiency exerts counter-apoptotic, antihypertensive, anti-atherosclerotic, anti-arrhythmic, antithrombotic effects and result in a reduction in the risk of visual loss in chronic glaucoma. The prophylactic nutritional supplementation of Mg
+2
that prevents the development of magnesium deficiencies, particularly in identifiable groups, will reduce the risks associated with hypomagnesemia and avoid the undesirable side effects associated with powerful Ca
+2
channel blockers.
(c) Zinc (Zn
+2
) and Copper (Cu
+2
)
Zn
+2
and Cu
+2
are cofactors for, and are reported to be inducers of, the antioxidant superoxide dismutase (CuZnSOD). Zn
+2
also binds the sulfhydryl groups of proteins, additionally protecting them from oxidation.
CuZnSOD enzymatically degrades the free radical superoxide (O
•
). Although O
•
itself is not as damaging to cell membranes as other free radicals, it spawns the highly toxic hydroxyl radical (OH
−
) via a Fenton reaction with iron. Because constitutively produ
Pearson Don C.
Richardson Kenneth T.
ChronoRX LLC
Spivack Phyllis G.
Townsend and Towsend and Crew LLP
LandOfFree
Clinical uses for L-arginine ascorbate and various... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Clinical uses for L-arginine ascorbate and various..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clinical uses for L-arginine ascorbate and various... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2854810